{"contentid": 487921, "importid": NaN, "name": "Cosela now launched in USA for people with extensive-stage SCLC", "introduction": "US oncology drug developer G1 Therapeutics and German family-owned pharma major Boehringer Ingelheim today announced that Cosela (trilaciclib) for injection is now available in the USA.", "content": "<p>US oncology drug developer G1 Therapeutics (Nasdaq: GTHX) and German family-owned pharma major Boehringer Ingelheim today announced that Cosela (trilaciclib) for injection is now available in the USA.</p>\n<p>The move follows the Food and Drug Administration&rsquo;s <a href=\"https://www.thepharmaletter.com/article/g1-therapeutics-rises-on-news-of-fda-green-light-for-cosela\">approval of Cosela</a> in February to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). It is the first and only therapy designed to help protect bone marrow (myeloprotection) when administered prior to treatment with chemotherapy.</p>\n<h2><strong>Sales forecast</strong></h2>\n<p>According to a posting on Seeking Alpha last year, if approved, trilaciclib could generate $500 million-$1 billion in revenues/year in small-cell lung cancer (69,000 patients worldwide).</p>\n<p>&ldquo;This is an exciting time for the combined G1 and Boehringer Ingelheim team as we are now able to provide Cosela, the first proactive multilineage myeloprotection therapy, to patients with extensive-stage small cell lung cancer,&rdquo; said Soma Gupta, chief commercial officer at G1 Therapeutics, adding: &ldquo;Our commitment includes ensuring excellence in support and access to Cosela; to that end, we are excited to launch the G1 to One Patient Support Program which is designed to provide access and affordability solutions to eligible patients.&rdquo;</p>\n<p>&ldquo;We are proud to help bring Cosela to the physicians and their patients who are in need of options when it comes to managing ES-SCLC treatment,&rdquo; said Dan Asch, head of commercial oncology at Boehringer Ingelheim Pharmaceuticals Inc. &ldquo;G1&rsquo;s experienced and passionate commercial and medical teams along with Boehringer Ingelheim&rsquo;s seasoned oncology team are eager to engage with the community to communicate the clinical benefits of this innovative therapy,&rdquo; he noted.</p>", "date": "2021-03-02 16:02:00", "meta_title": "Cosela now launched in USA for people with extensive-stage SCLC", "meta_keywords": "Boehringer Ingelheim, G1 Therapeutics, Cosela, Trilaciclib, Launch, USA, Myelosuppression, Lung cancer, ES-SCLC", "meta_description": "Cosela now launched in USA for people with extensive-stage SCLC", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-02 16:00:35", "updated": "2021-03-02 16:09:50", "access": NaN, "url": "https://www.thepharmaletter.com/article/cosela-now-launched-in-usa-for-people-with-extensive-stage-sclc", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "g1_therapeutics_large.png", "image2id": "g1_therapeutics_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immunologicals, Oncology", "topic_tag": "One to Watch Companies, Product Launch", "geography_tag": "Germany, USA", "company_tag": "Boehringer Ingelheim, G1 Therapeutics", "drug_tag": "Cosela, trilaciclib", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-02 16:02:00"}